These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 19087568)

  • 1. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
    Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
    Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
    Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
    Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
    Alberts DS; Liu PY; Wilczynski SP; Clouser MC; Lopez AM; Michelin DP; Lanzotti VJ; Markman M;
    Gynecol Oncol; 2008 Jan; 108(1):90-4. PubMed ID: 17949799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
    Power P; Stuart G; Oza A; Provencher D; Bentley JR; Miller WH; Pouliot JF
    Gynecol Oncol; 2009 Sep; 114(3):410-4. PubMed ID: 19520420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
    Kurtz JE; Kaminsky MC; Floquet A; Veillard AS; Kimmig R; Dorum A; Elit L; Buck M; Petru E; Reed N; Scambia G; Varsellona N; Brown C; Pujade-Lauraine E;
    Ann Oncol; 2011 Nov; 22(11):2417-2423. PubMed ID: 21402619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
    Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
    J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
    Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
    Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.
    Markman M; Moon J; Wilczynski S; Lopez AM; Rowland KM; Michelin DP; Lanzotti VJ; Anderson GL; Alberts DS
    Gynecol Oncol; 2010 Mar; 116(3):323-5. PubMed ID: 20044128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
    Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
    Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
    Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
    Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).
    Fujiwara H; Ushijima K; Nagao S; Takei Y; Shimada M; Takano M; Yoshino K; Kawano Y; Hirashima Y; Nagase S; Nishio S; Nishikawa T; Ito K; Shoji T; Kimura E; Takano T; Sugiyama T; Kigawa J; Fujiwara K; Suzuki M
    Int J Clin Oncol; 2019 Oct; 24(10):1284-1291. PubMed ID: 31127479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian Carcinoma.
    Rose PG; Radeva M; Michener CM; Link N; Adbul-Karim F
    Int J Gynecol Cancer; 2017 Jun; 27(5):907-911. PubMed ID: 28498259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer.
    Rapoport BL; Vorobiof DA; Slabber C; Alberts AS; Hlophe HS; Mohammed C
    Int J Gynecol Cancer; 2009 Aug; 19(6):1137-41. PubMed ID: 19820382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
    Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
    Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
    Gladieff L; Ferrero A; De Rauglaudre G; Brown C; Vasey P; Reinthaller A; Pujade-Lauraine E; Reed N; Lorusso D; Siena S; Helland H; Elit L; Mahner S
    Ann Oncol; 2012 May; 23(5):1185-1189. PubMed ID: 21976386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
    Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
    J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
    Pignata S; Scambia G; Ferrandina G; Savarese A; Sorio R; Breda E; Gebbia V; Musso P; Frigerio L; Del Medico P; Lombardi AV; Febbraro A; Scollo P; Ferro A; Tamberi S; Brandes A; Ravaioli A; Valerio MR; Aitini E; Natale D; Scaltriti L; Greggi S; Pisano C; Lorusso D; Salutari V; Legge F; Di Maio M; Morabito A; Gallo C; Perrone F
    J Clin Oncol; 2011 Sep; 29(27):3628-35. PubMed ID: 21844495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).
    Koinis F; Polyzos A; Christopoulou A; Zafeiriou Z; Emmanouilidis C; Papadimitraki E; Kalykaki A; Kalbakis K; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):819-25. PubMed ID: 24531559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.